Reported 7 months ago
Eli Lilly is closer to FDA approval for its new Alzheimer's treatment, donanemab, which can potentially uplift the drug market. Analysts believe the addition of Lilly's product could help accelerate market uptake due to its expected approval in the near future. However, challenges in diagnosis and treatment accessibility may hinder patient access. The drug's incremental benefits in slowing cognitive decline are promising, but the need for infrastructure for infusions poses a barrier. The market potential for Alzheimer's treatments is estimated to grow to $10-20 billion over time, but considerable time and effort are required for widespread adoption.
Source: YAHOO